Professor Mark Britton, vice-president of the British Lung Foundation, said the NICE guidance should make it "significantly easier" for clinicians "to set up appropriate systems to treat with this medication". "The approval of omalizumab improves the options available to the minority of people with asthma who are classified as having this more severe form, and sets clear standards for the NHS in England and Wales on how it should be used." Gillian Leng, deputy chief executive of NICE, said: "Severe persistent asthma greatly restricts the quality of life of the individual and can result in limited physical activity, continuous daytime symptoms and frequent symptoms at night. The NICE ruling comes a month after the drug was approved for patients in Scotland. The treatment of asthma sufferers currently costs the NHS almost £9billion a year. The decision is expected to benefit 6,000 patients a year and will save the NHS money because 80 per cent of what is spent on asthma goes on the 20 per cent of people with the most severe symptoms. He said it was expected to become available to patients within the next three months. "This treatment really can mean the difference between a life worth living and having no quality of life at all." "Xolair will be suitable for a small number of these people and will literally transform their lives. "Existing asthma treatments just don't work for around half a million people across the UK living with difficult-to-control asthma. The charity Asthma UK said it was "thrilled" by the decision of the National Institute for Health and Clinical Excellence to give the go-ahead for Xolair.Īsthma UK chief executive Neil Churchill said: "This is a victory for people with severe, allergic asthma, who have fought to receive this life-changing drug. The drug costs £250 per jab and most patients will require two a month - costing £6,000 a year. Trials of Xolair, also known as omalizumab, found that it cut the risk of asthma attack by 55 per cent and reduced hospital admissions by a half. Previous treatments - such as inhalers and oral steroids - work by suppressing the symptoms rather than tackling the causes.īut Xolair blocks the allergic triggers responsible for attacks. These often fail to control symptoms and can cause kidney damage and weight gain.Īsthma attacks occur when the body detects a foreign body in the system but overreacts by producing large amounts of antibodies. Until now severe asthma sufferers - around one in ten of those with the disease - have had to rely on large doses of powerful steroid drugs. The treatment could cut the toll of 1,400 Britons who die from asthma each year, as well as the 69,000 patients who end up in hospital. The Government's health watchdog has ruled that Xolair, which halves the risk of an asthma attack, should be given to all patients with the severe form of the disease.
It does not store any personal data.Doctors have been given the go-ahead to prescribe an asthma "wonder drug" on the Health Service. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously.
Necessary cookies are absolutely essential for the website to function properly.
0 kommentar(er)
